NCT03452228 - Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 7, 2018

Primary Completion Date

December 17, 2019

Study Completion Date

July 23, 2020

Conditions

Severe Hypertriglyceridemia (sHTG)

Interventions

DRUG

evinacumab

Administered by Intravenous (IV)

DRUG

Placebo

Administered by Intravenous (IV)

Trial Locations (17)

10029

Regeneron Research Facility, New York

15261

Regeneron Research Facility, Pittsburgh

19104

Regeneron Research Facility, Philadelphia

30328

Regeneron Research Facility, Atlanta

33434

Regeneron Research Facility, Boca Raton

53226

Regeneron Research Facility, Milwaukee

66160

Regeneron Research Facility, Kansas City

75390

Regeneron Research Facility, Dallas

77030

Regeneron Research Facility, Houston

80131

Regeneron Research Facility, Napoli

G7H7K9

Regeneron Research Facility, Chicoutimi

G1V4W2

Regeneron Research Facility, Québec

00161

Regeneron Research Facility, Rome

B15 2TH

Regeneron Research Facility, Birmingham

NW3 2QG

Regeneron Research Facility, London

SE1 7EH

Regeneron Research Facility, London

M13 9WL

Regeneron Research Facility, Manchester

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY